Please note that these articles are provided for information only and any questions should be directed to your doctor.
Get Involved
There are so many ways you can help make a difference in the lives of patients and families today.
Stay Informed!
Sign up for one
of our newsletters.
of our newsletters.
Sign Up Today
Research News
Research News
- Home
- Research
- Research News
- Clinical Trials News
Clinical Trials News
-
A Decade of Impact
November 2022 – Ten years ago, Ontario and Canada saw a decline in clinical trials activity. In response, the Government of Ontario, along with hospitals, universities, industry, research ethics boards and others came together to establish Clinical Trials Ontario (CTO) with a goal of strengthening, promoting and capitalizing on Ontario’s advantages for conducting quality clinical trials.
-
Researchers shrink brain tumours with gold nanoparticles, develop ‘mini brains’ to study psychiatric disorders
November 2022 – Researchers at the University of Toronto are inching closer to realizing a life-saving brain cancer treatment by using gold nanoparticles to make radiation therapy more effective and less toxic for patients
-
Introduction to Clinical Trials - Dr. Dawn Richards
April 2022
-
In a world first, clinical trial delivers therapy to metastatic cancer in the brain
February 2022 – Interdisciplinary team shows ultrasound focused therapy allows drug to get past the blood-brain barrier.
-
Anticancer Drug Shrinks Tumors in Almost a Third of Patients in Recurrent Glioblastoma Trial
February 2022 – A clinical trial has found that selinexor, the first of a new class of anti-cancer drugs, was able to shrink tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer.
-
New clinical trial at The Neuro offers hope to brain cancer patients with a recurrence of glioblastoma
June 2021 – “Hope is that adaptive multi-modal trial will speed up how quickly discoveries can be made and new potentially efficacious drugs can be available for use.”
-
Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer
March 2021
-
Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiforme
February 2021 – Kintara Therapeutics Inc has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 drug.
-
Kazia Therapeutics’ (ASX:KZA) brain cancer drug selected for international study
December 2020 – “Kazia Therapeutics’ (KZA) paxalisib drug has been chosen for a multiple-therapy clinical trial in diffuse midline glioma.”
-
Next generation BRAF inhibitor cancer drug shows promise in early patient trial
October 2020 – A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial.
-
Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study
October 2020 – Midatech Pharma is pleased to announce encouraging headline results from a Phase I study at the University of California, San Francisco in patients with Diffuse Intrinsic Pontine Glioma (“DIPG”).
-
BioMark Team Secures Health Canada Letter of No Objection for Its Glioblastoma Clinical Trial
August 2020 – “BioMark Diagnostics Inc. is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA.”
-
New drug targets for lethal brain cancer discovered
August 2020 – Researchers engineered a new mouse model for studying glioblastoma, the most aggressive type of brain cancer.
-
Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit
December 2019
-
Kazia Therapeutics shares surge after positive early phase II study results for GDC-0084 in brain cancer patients
November 2019
-
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
September 2019
-
Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug
September 2019
-
Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
September 2019
-
Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine
August 2019
-
Henry Ford Cancer Institute Enrolls First Patient in World's Largest Brain Cancer Clinical Trial
August 2019
-
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
June 2019
-
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
May 2019
-
Viruses that kill bacteria could tackle 'incurable' brain cancers
April 2019
-
New clinical trial will determine if gliomas respond to immunotherapy
April 2019